Clinical Convergence®: Patient and Provider Perspectives in IBD

Title:

Clinical Convergence®: Patient and Provider Perspectives in IBD

Topic: Gastroenterology
Relevant Terms: IBD
Primary Audience: Gastroenterologists and gastroenterology nurse practitioners (NPs) and physician assistants (PAs)
Launch Date: 12-Jan-17
Credits: 2.25 AMA PRA Category 1 Credits
Expiration Date: 11-Jan-18
Curriculum Name: Clinical Convergence: Patient and Provider Perspectives in IBD Enduring

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Compare and contrast the clinical effects of the various IBD therapies
  2. Select individualized treatments for patients with IBD that maximize the opportunity to achieve remission and avoid relapse while minimizing toxicity
  3. Utilize available disease progression and drug monitoring strategies for patients with IBD
  4. Implement appropriate practice measures and quality of care process and outcomes measures in managing patients with IBD

    Faculty

    Sunanda Kane, MD, MSPH (National Chair)
    Professor of Medicine
    Mayo Clinic Rochester
    Rochester, MN
    Sasha Taleban, MD (Regional Chair)
    Assistant Professor
    Director, Inflammatory Bowel Disease (IBD) Program
    University of Arizona
    Tucson, AZ
    Gary R. Lichtenstein, MD
    Professor of Medicine
    Director, IBD Center
    University of Pennsylvania School of Medicine
    Philadelphia, PA
    Millie D. Long, MD, MPH
    Associate Professor of Medicine
    Division of Gastroenterology and Hepatology
    University of North Carolina
    Chapel Hill, NC
    Derek R. Patel, MD
    Associate Clinical Services, Chief
    Hillcrest Gastroenterology
    San Diego, CA
    CONTINUING MEDICAL EDUCATION
    Accreditation Statement
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati, the Crohn’s & Colitis Foundation of America, and RMEI Medical Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
     
    Designation Statement
    The University of Cincinnati designates this enduring material activity for a maximum of 2.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    FACULTY DISCLOSURE DECLARATION
    According to the disclosure policy of the University of Cincinnati, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interest related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.
    Disclosure will be made at the time of activity.
     
    In accordance with the ACCME Standards for Commercial Support, the speakers for this course have been asked to disclose to participants the existence of any financial interest and/or relationship(s) (e.g., paid speaker, employee, paid consultant on a board, and/or committee for a commercial company) that would potentially affect the objectivity of his/her presentation or whose products or services may be mentioned during their presentation. The following disclosures were made:
     
    Sunanda Kane, MD, MSPH, discloses the following relationships with commercial interests:
    • Advisory Board: 11 Health
    • Consultant: AbbVie, Samsung
    • Officer or Board Member: ACG, ABIM
    • Grant Recipient: UCB 
    Sasha Taleban, MD, has no relevant relationships to disclose.
     
    Gary R. Lichtenstein, MD, discloses the following relationships with commercial interests:
    • Consultant: Abbott/AbbVie, Actavis, Alaven, Hospira, Luitpold/American Regent, Pfizer Pharmaceuticals, Romark, Takeda
    • Consultant/Research: Celgene, Ferring, Janssen Biotech, Prometheus Laboratories, Receptos, Salix Pharmaceuticals/Valeant, Santarus, Shire Pharmaceuticals, UCB
    • Speaker for CME activities: Ironwood, Luitpold/American Regent
    • Editor (Honorarium): Clinical Advances in Gastroenterology, Gastro-Hep Communications, Springer Science and Business Media
    • Author (Honorarium): McMahon Publishing, Up-To-Date
    • Book Royalty: SLACK, Inc.
    Millie D. Long, MD, MPH, discloses the following relationships with commercial interests:
    • Advisory Board: AbbVie, Pfizer, Takeda
    • Consultant: AbbVie, Takeda, Theravance
    • Research Support: Takeda
    • Speaker for CME activities: AbbVie
    Derek R. Patel, MD, discloses the following relationships with commercial interests:
    • Speaker: AbbVie
    • Advisory Board: AbbVie
    The planners and managers reported the following financial relationships or relationships
    to products or devices they or their spouse/life partner have with commercial interests
    related to the content of this CME activity:
     
    Crohn’s & Colitis Foundation of America
    Orna Ehrlich, MPH, has no relevant relationships to disclose.
     
    RMEI Medical Education, LLC
    Sherri Kramer, MD, has no relevant relationships to disclose.
    Kyra Sheahan has no relevant relationships to disclose.
    Faith Reidenbach has no relevant relationships to disclose.
    Nora Hartley has no relevant relationships to disclose.
     
    University of Cincinnati
    Susan P. Tyler, MEd, CMP, CHCP, FACEHP, Director, has no relevant relationships to disclose.
    Rick E. Ricer, MD, Professor Emeritus, has no relevant relationships to disclose.
    Deborah Cole, BS, Program Coordinator, has no relevant relationships to disclose.
     
    OFF-LABEL DISCLOSURE STATEMENT
    Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.
     
    LEARNER ASSURANCE STATEMENT
    The University of Cincinnati is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.
     
    DISCLAIMER STATEMENT
    The opinions expressed during the enduring material activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
      
    Estimated time to complete: 2.25 hours
    Medium: Internet

    FEE INFORMATION
    There is no fee for this educational activity.

    COMMERCIAL SUPPORT
    This activity is supported by independent medical education grants from AbbVie, Celgene Corporation, Salix Pharmaceuticals, Takeda Pharmaceuticals U.S.A., Inc., and UCB, Inc.

    HOW TO RECEIVE CREDIT
    By completing the curriculum challenge (at the beginning and again at the end of the activity), the pre-test, reviewing the course content, and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 2.25 AMA PRA Category 1 Credits™. A statement of credit will be available to print from your user history page.
    Users must:
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the activity evaluation.
    Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
     
    Contact Information:
    Accreditation Support
    Please contact the University of Cincinnati, Continuing Medical Education Department at uccme@uc.edu or call 513-558-7277.
     
    Technical Support:
    For any technical issues or issues with your CME Certificate, please visit: http://www.realcme.com/cms/support-center.
     
    COURSE VIEWING REQUIREMENTS
    Supported Browsers:
    Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6.0+ for Mac OSX 10.7 and above